Stadiul cunoaşterii.... - Gr.T. Popa

Corelaţii clinice,imunohistochimice şi morfopatologice în unele tumori de ovar
Coordonator ştiinţific:Prof.Dr.Zenovia Florentina Pricop
__________________________________________________Doctorand:Ioana Buda
19. Boyd J., Sonoda Y., Federici M.G., Clinicopathologic features of BRCA-linked and sporadic ovarian cancer,
JAMA, 2000, 283: 2260-2265
20. Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Comparison of standard and
CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin
Oncol. Feb 1999;17(2):501-8.
21. Burger CW, van Doorn HC, van der Valk P & Bonfre`r HMG 1999 Oestrogen, progesterone and androgen
receptors in ovarian neoplasm; correlation between immunohistochemical and biochemical receptor analysis.
International Journal of Gynecological Cancer 9 17.
22. Burger, H. G., Baillie, A., Drummond, A. E., Healy, D. L., Jobling, T., Mamers, P. et al. (1998). Inhibin and
ovarian cancer. J. Reprod. Immunol. 39(1–2), 77–87.
23. Burger, H. G., Robertson, D. M., Cahir, N., Mamers, P., Healy, D. L., Jobling, T. et al. (1996). Characterization
of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Clin. Endocrinol. (Oxf.);44(4),
413–418.
24. Buţureanu S. Patologie ginecologică benignă. Institutul European 2004.
25. Campbell S, Bhan V, Royston J, et al. Screening for early ovarian cancer. Lancet 1988;1:710-1.
26. Campbell S, Bhan V, Royston P, et al. Transabdominal ultrasound screening for early ovarian cancer BMJ
1989;299:1363-7.
27. Cannistra SA: Cancer of the ovary. N Engl J Med 329 (21): 1550-9,1993.Carmeliet P, Jain RK. Angiogenesis in
cancer and otHER disease. Nature 2000;407:249–57.
28. Carlson JK, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med. 121(2): 124-32, Jul 1994.
29. Carmeliet P, Jain RK. Angiogenesis in cancer and otHER disease. Nature 2000;407:249–57.
30. Casazza S.-L’espressione della fosfoproteina P53 in patologia,Pathologica,1993,85:321-334
31. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol.
2002;117:944–951
32. Chan W. Y., Cheung K. K., Schorge J. O., Huang L. W., Welch W. R., Bell D. A., Berkowitz R. S., Mok S. C. –
Bcl-2 and p53 Proteins Expression, Apoptosis and p53 Mutation in Human Epithelial Ovarian Cancers,
American Journal of Pathology, 2000;156: 409- 417
33. Charpin C, Bhan AK, Zurawski VR Jr, Scully RE. Carcinoembryonic antigen (CEA) and carbohydrate
determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an
34.
immunohistochemical study with the use of monoclonal antibodies. Int J Gynecol Pathol. 1982;1(3):231-45.
Chatterjee M, Mohapatra S, Ionan A, et al. Diagnostic markers of ovarian cancer by high-throughput antigen
cloning and detection on arrays. Cancer Res. Jan 15 2006;66(2):1181-90.Chen DX, Schwartz PE, Li XG, Yang
Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
Obstet Gynecol. Jul 1988;72(1):23-7.
35. Cuatrecacas M., Villanueva A., Matias-Guiu X. Prat J., K-ras mutation in mucinous ovarian tumors. A
clinicopathologic and molecular study of 95 cases, Cancer 1997; 79: 1581-1586
36. Czernobilsky B, Moll R, Levy R, et al. Co-expression of cytokeratin and vimentin filaments in mesothelial,
granulose and rete ovarii cells of the human ovary. Eur J Cell Biol 1985;37:175–90.
37. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of
thrombospondin, I. Science 1994;265:1582–4.
77